Navigation Links
InterMune to Present at Canaccord Adams Conference
Date:8/7/2009

BRISBANE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Canaccord Adams 29th Annual Global Growth Conference in Boston on August 12, 2009 at 10:30 a.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
2. InterMune to Release Second Quarter Financial Results on August 6
3. InterMune to Present at Goldman Sachs Healthcare Conference
4. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
5. InterMune to Release First Quarter Financial Results on April 30
6. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
7. InterMune to Present at Canaccord Adams Hepatitis C Conference
8. InterMune to Present at Citis 4th Annual Biotech Day
9. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
10. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
11. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... CA (PRWEB) April 01, 2015 ... Personalized Medicine , presented two scientific posters at ... Utah, last week. The four-day event was hosted at ... genetic specialists dedicated to educating genetic and genomic professionals ... presented Genetics and Insomnia: Study on the Role of ...
(Date:4/1/2015)... , April 1, 2014 /CNW/ - Canada,s ... Prices Review Board,s (PMPRB) newly released report on Cost Drivers ... Rx&D notes that, according to the report, the rates of ... years, reaching a low of -0.8 percent in 2012/13 for ... that any study that examines the costs of medicines without ...
(Date:4/1/2015)... and NEW YORK ... Inc. (NASDAQ:  PTBI), a biopharmaceutical company advancing protein ... provided an overview of the Company,s 2014 achievements ... achievements below demonstrate the progress the Company has ... multiple corporate partnerships for its MuGard programs, the ...
(Date:4/1/2015)... April 1, 2015  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today ... held full service global investment bank specializing in ... industry note featuring Spherix. The report, ... Senior Analyst at Chardan, was published on March ...
Breaking Biology Technology:Proove Biosciences Presents Research Studies at Annual Clinical Genetics Meeting 2015 2Rx&D responds to PMPRB report: overall impact of medicines must always be considered 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 5PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 6Chardan Capital Issues Industry Note Covering Spherix 2Chardan Capital Issues Industry Note Covering Spherix 3
... 2011 During a ,Day of Science, more than 30 ... what it was like to be scientists for a day ... Inc. (S2S). The "A Day in the Life of a ... programs offered by S2S that seeks to address the fact ...
... (Nasdaq: DNDN ) today announced that management will present ... in New York City, NY on May 25, 2011 at 1:00 ... Palos Verdes, CA on June 7, 2011 at 2:00 p.m. PT ... available for replay from Dendreon,s website, www.dendreon.com .  If you ...
... BRISBANE, Calif., May 19, 2011 InterMune, Inc. (NASDAQ: ... of its 2011 Analyst Day presentations on Thursday, May ... in New York.  Presentations by InterMune,s executive management team ... and a comprehensive update of InterMune,s commercial and scientific ...
Cached Biology Technology:Local Partnership Addresses Lagging Scores and Interest in Science and Math Among Students 2Local Partnership Addresses Lagging Scores and Interest in Science and Math Among Students 3InterMune to Webcast 2011 Analyst Day Presentations 2
(Date:3/12/2015)... March 12, 2015 WHEN:Tuesday, March 17, 2015 ... http://bit.ly/1G7Os0L . SPEAKERS: , Frost & Sullivan ... http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies must ... in several different markets and industries. This is ... an uptrend. Join Frost & ...
(Date:3/11/2015)...   The Sync Project™ today announced ... and harness music to improve health. The platform ... measurements of physiology, enabling the study of the ... populations. It is designed for medical and health ... studies and accelerate the discovery of the clinical ...
(Date:3/10/2015)... BOULDER, Colo. , March 10, 2015 ... Space Flight "Personalized Medicine in Human ... Ph.D. and Thomas J. Goodwin , Ph.D. was ... articles of the past two years. Specifically, ... three most downloaded scientific papers published in 2013 and ...
Breaking Biology News(10 mins):Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
... human DNA is the genetic equivalent of e-mail spam: short ... more of themselves. After starting out in our primate ... called an Alu retrotransposon now takes up 10 percent of ... newborn baby has a new Alu retrotransposon somewhere in its ...
... of how neurons and muscle cells establish lifelong communication ... may be mutated and/or attacked in muscular dystrophy. ... direct construction of the nerve-muscle contact or synapse. MuSK ... talk so synpases can form and receptors that enable ...
... are exposed to a wide range of environmental threats ... life, throughout their youth and into adulthood. Writing in ... Environmental Health scientists from the World Health Organization ... both industrialized and developing countries to assess the environmental ...
Cached Biology News:Mapping a clan of mobile selfish genes 2Mapping a clan of mobile selfish genes 3Mediator in communication between neurons and muscle cells found 2Childhood environmental health 2
CCNI Antibody...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
3M Imidazole Solution 125 ml...
Rabbit polyclonal to NCoR2, prediluted ( Abpromise for all tested applications). entrezGeneID: 9612 SwissProtID: Q9Y618...
Biology Products: